🇺🇸·18h agoResearch
NCT05038735: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Study type: INTERVENTIONAL. Phase: PHASE3.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- July 8, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE3.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
University of Minnesota/2h ago
Saving a farmer’s life could be as simple as listening, offering hope
University of Minnesota/2h ago
University of Minnesota supports equine community
University of Minnesota/2h ago
Does the order in which you eat food matter?
University of Minnesota/2h ago